zanubrutinib
Showing 26 - 50 of 66
Immune Thrombocytopenia, Treatment Trial in Tianjin (Zanubrutinib)
Recruiting
- Immune Thrombocytopenia
- Treatment
- Zanubrutinib
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
Jan 19, 2022
Immune Thrombocytopenia Trial (Zanubrutinib, Dexamethasone)
Not yet recruiting
- Immune Thrombocytopenia
- Zanubrutinib
- Dexamethasone
- (no location specified)
May 6, 2022
B-cell Malignancies Trial in Australia (Zanubrutinib, Fluconazole, Diltiazem)
Completed
- B-cell Malignancies
- Zanubrutinib
- +4 more
-
Concord, New South Wales, Australia
- +6 more
Jul 18, 2022
Immune Thrombocytopenia Trial in Beijing (Zanubrutinib, Eltrombopag)
Not yet recruiting
- Immune Thrombocytopenia
- Zanubrutinib
- Eltrombopag
-
Beijing, Beijing, ChinaPeking University Insititute of Hematology, Peking University Pe
May 6, 2022
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma Trial in Boston (Venetoclax, Zanubrutinib)
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma
- Venetoclax
- Zanubrutinib
-
Boston, Massachusetts
- +2 more
Mar 16, 2022
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) Trial in United States (Zanubrutinib, Obinutuzumab,
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Leukemia (SLL)
- Zanubrutinib
- +2 more
-
Evanston, Illinois
- +7 more
Sep 9, 2022
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)
Recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Rituximab
- Zanubrutinib
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022
Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation Trial in Zhengzhou (Rituximab, Zanubrutinib,
Recruiting
- Diffuse Large B Cell Lymphoma
- +2 more
- Rituximab
- +5 more
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jan 22, 2022
Diffuse Large B Cell Lymphoma Trial in Shanghai (zanubrutinib)
Recruiting
- Diffuse Large B Cell Lymphoma
- zanubrutinib
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 13, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma Trial in Australia, China (BGB-10188,
Recruiting
- Chronic Lymphocytic Leukemia
- +9 more
- BGB-10188
- +2 more
-
Adelaide, Australia
- +12 more
Jan 6, 2023
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Nanjing, Nanjin (Zanubrutinib, Lenalidomide, Rituximab)
Recruiting
- Non Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma
- Zanubrutinib
- +6 more
-
Nanjing, Jiangsu, China
- +1 more
Mar 9, 2022
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic
Not yet recruiting
- Recurrent Transformed Chronic Lymphocytic Leukemia
- +7 more
- Biospecimen Collection
- +9 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
May 15, 2023
Richter Transformation Trial in Austria, Denmark, Germany (Tislelizumab, Zanubrutinib)
Recruiting
- Richter Transformation
- Tislelizumab
- Zanubrutinib
-
Vienna, Austria
- +11 more
Mar 8, 2022
Healthy, Male Trial in Daytona Beach (Zanubrutinib, Rifabutin)
Completed
- Healthy
- Male
- Zanubrutinib
- Rifabutin
-
Daytona Beach, FloridaCovance Clinical Research Unit
Aug 30, 2021
Lymphoma, Leukemia Trial in Australia, China (Zanubrutinib, Tislelizumab)
Completed
- Lymphoma
- Leukemia
- Zanubrutinib
- Tislelizumab
-
Darlinghurst, New South Wales, Australia
- +9 more
Mar 16, 2022
Primary Vitreoretinal Lymphoma Trial in Beijing (Methotrexate, Rituximab, Zanubrutinib)
Recruiting
- Primary Vitreoretinal Lymphoma
- Methotrexate
- +2 more
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 19, 2021
COVID-19 Pulmonary Complications, COVID-19 Trial in United States (Zanubrutinib, Supportive Care, Placebo)
Completed
- COVID-19 Pulmonary Complications
- COVID-19
- Zanubrutinib
- +2 more
-
Scottsdale, Arizona
- +17 more
Feb 25, 2022
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma Trial in China (Zanubrutinib)
Recruiting
- Relapsed Diffuse Large B-cell Lymphoma
- Refractory Diffuse Large B-cell Lymphoma
- Zanubrutinib
-
Hefei, Anhui, China
- +21 more
Mar 2, 2022
Non-GCB/ABC DLBCL Trial in Suzhou (Zanubrutinib, Rituximab, Cyclophosphamide)
Recruiting
- Non-GCB/ABC Diffuse Large B-Cell Lymphoma
- Zanubrutinib
- +5 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Apr 12, 2021
Relapsed/Refractory DLBCL Trial in China (Zanubrutinib, Lenalidomide)
Recruiting
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Zanubrutinib
- Lenalidomide
-
Beijing, Beijing, China
- +9 more
Aug 11, 2021
Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos Trial in Shanghai (Zanubrutinib, Tislelizumab)
Recruiting
- Primary Mediastinal Large B Cell Lymphoma
- EBV-Positive DLBCL, Nos
- Zanubrutinib
- Tislelizumab
-
Shanghai, Shanghai, ChinaRuijin Hospital
Mar 29, 2021
DLBCL, Transformed Follicular Lymphoma to DLBCL, Transformed Marginal Zone Lymphoma to DLBCL Trial in Columbus
Recruiting
- Diffuse Large B-Cell Lymphoma
- +2 more
- Cyclophosphamide
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 23, 2022
Diffuse Large B-cell Lymphoma Trial in China (Zanubrutinib)
Completed
- Diffuse Large B-cell Lymphoma
- Zanubrutinib
-
Beijing, Beijing, China
- +10 more
Oct 11, 2021